Dr. Divaya Bhutani is a professional in the field of hematology. This medical discipline involves the study of blood, blood-forming organs, and various blood disorders, encompassing conditions from common anemias to complex blood cancers. Dr. Bhutani’s work contributes to understanding and treating these health challenges.
Dr. Bhutani’s Expertise and Practice
Dr. Bhutani’s expertise covers blood cancers and non-malignant blood disorders. He specializes in treating multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. His practice also extends to other serious conditions such as Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and various forms of leukemia, including acute lymphoid leukemia and acute myeloid leukemia.
His clinical work also addresses non-cancerous blood conditions, including different types of anemia like iron deficiency anemia and hemolytic anemia, along with bleeding and clotting disorders. Dr. Bhutani currently serves as a hematologist and oncologist at NewYork-Presbyterian Lawrence Hospital and holds a position as an Assistant Professor of Medicine at Columbia University Irving Medical Center.
Her Approach to Patient Care
Dr. Bhutani’s philosophy of care centers on providing personalized treatment plans tailored to each patient’s specific needs. He emphasizes a multidisciplinary team approach, ensuring that patients benefit from the collective knowledge of various medical specialists.
He places importance on patient education, empowering individuals to understand their condition and treatment options. Dr. Bhutani ensures that patients are well-informed and actively involved in decisions regarding their care.
Impact and Contributions
Dr. Bhutani’s influence extends beyond direct patient care through his contributions to research and academic medicine. He is recognized as an expert in multiple myeloma therapies and treatment strategies, with extensive publications in the field. His research focuses on developing novel therapies for multiple myeloma and studying complications associated with stem cell transplantation.
He has presented his work at annual medical meetings of the American Society of Hematology and has been featured in medical journals such as Pharmacology & Therapeutics and Journal of Clinical Oncology. Dr. Bhutani is also an active member of national cooperative groups like the Southwest Oncology Group (SWOG), where he serves as a principal investigator on clinical trials. For instance, he leads a prospective trial (S2005) evaluating the use of Venetoclax in patients with Waldenstrom’s Macroglobulinemia and is developing a trial using anti-amyloid antibody CAEL-101 for renal AL Amyloidosis.